Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Not applicable Interventional

RESET System Pivotal Trial (Rev F)

ClinicalTrials.gov ID: NCT04101669

Public ClinicalTrials.gov record NCT04101669. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET® System for Glycemic Improvement in Patients With Inadequately Controlled Type 2 Diabetes and Obesity

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study. A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and effectiveness of the RESET System plus moderate intensity lifestyle and dietary counseling compliant with 2024 ADA Standard of Care as compared to a sham control receiving moderate intensity lifestyle and dietary counseling. Both the treatment and sham group will practice medical management compliant with STEP-1 Study Guidelines. Patients will be randomized 3 (RESET):1 (Sham).

Study identification

NCT ID
NCT04101669
Recruitment status
Recruiting
Study type
Interventional
Phase
Not applicable
Lead sponsor
Morphic Medical Inc.
Industry
Enrollment
264 participants

Conditions and interventions

Interventions

Device · Other

Eligibility (public fields only)

Age range
22 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 8, 2019
Primary completion
Nov 30, 2025
Completion
Nov 30, 2026
Last update posted
Jul 17, 2024

2019 – 2026

United States locations

U.S. sites
7
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
MedStar Health Research Institute Washington D.C. District of Columbia 20010 Recruiting
University of Miami Hospital Miami Florida 33166 Recruiting
Brigham and Women's Hospital Boston Massachusetts 02115 Recruiting
Michigan Medicine, Division of Gastroenterology and Hepatology Ann Arbor Michigan 48109 Recruiting
Weill Cornell Medicine New York New York 10021 Recruiting
Cleveland Clinic Cleveland Ohio 44195 Recruiting
Baylor College of Medicine Houston Texas 77030 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04101669, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 17, 2024 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04101669 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →